Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07818304) titled 'SRT Combined With Envafolimab and Endostar in the First-line Treatment of Advanced NSCLC' on Sept. 8.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: The First People's Hospital of Lianyungang
Condition:
Non Small Cell Lung Cancer
Lung Neoplasms
Intervention:
Radiation: Stereotactic Radiation Therapy
Drug: Envafolimab
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: October 2026
Target Sample Size: 61
Countries of Recruitment:
China
To know more, v...